Clinical Trials
Extending neoadjuvant chemotherapy yields similar EFS in pancreatic cancer trial
Reni et alEClinicalMedicine

In patients with resectable and borderline resectable (R/BR) pancreatic ductal adenocarcinoma (PDAC), extending neoadjuvant chemotherapy does not improve event-free survival (EFS) over shorter preoperative therapy, according to findings from the second randomisation of the phase 3 PACT-21/CASSANDRA trial.
The open-label, 2 × 2 factorial trial conducted across 17 academic hospitals in Italy evaluated 165 patients aged 18 to 75 years with pathologically confirmed R/BR PDAC. Following initial treatment with either PAXG (cisplatin, nab-paclitaxel, capecitabine, and gemcitabine) or mFOLFIRINOX, patients without disease progression or limiting toxicity after 4 months underwent a second randomisation to receive an additional 2 months of the same regimen either preoperatively (long course, n = 86) or postoperatively (short course, n = 79).
In the intention-to-treat population, long-course preoperative chemotherapy yielded no significant benefit in the primary endpoint of EFS compared to short-course treatment (unadjusted HR 0.98, 95% CI 0.68–1.41; P = 0.90). Overall survival data are not yet mature.
Despite the equivalent EFS, extended preoperative chemotherapy conferred notable benefits across several secondary oncologic and pathological endpoints. Patients in the long-course arm achieved a significantly higher CA19-9 response rate (97% [58/60] vs 84% [41/49]; P = 0.02), a higher rate of pathological complete response (5% [4/86] vs 0% [0/79]; P = 0.05), and an increased N0 resection rate (45% [39/86] vs 27% [21/79]; P = 0.01). Chemotherapy dose-density was also improved in the longer preoperative arm. The trial authors concluded that short and long preoperative durations provide comparable EFS, indicating that clinical efforts should focus on identifying more active systemic regimens and establishing optimal postoperative therapeutic strategies.
Key Takeaways
- Extending neoadjuvant chemotherapy to 6 months did not improve event-free survival compared with 4 months of preoperative therapy in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma (unadjusted HR 0.98, 95% CI 0.68–1.41; P = 0.90).
- Long-course preoperative chemotherapy significantly increased CA19-9 response rates (97% vs 84%, P = 0.02), lymph node-negative (N0) resections (45% vs 27%, P = 0.01), and pathological complete responses (5% vs 0%, P = 0.05).
- Chemotherapy dose-density was improved with extended preoperative delivery, while overall survival data remain immature.
Read the original sourceEClinicalMedicine
